OwnershipPublicly listed · Nasdaq: HUMASEC EDGAR company record and tickers file (Nasdaq: HUMA) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: HUMA, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
7developments published
$1.6MUS federal obligations on record
1federal awards
Sep 22, 2026latest development
Timeline
- Sep 22, 2026 · Leadership change
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Company-reported - Aug 12, 2026 · Reported results
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Company-reported - Jul 31, 2026 · Listing notice
Humacyte reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
Regulatory filing - Jun 10, 2026 · Financing
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Company-reported - Jun 10, 2026 · Company announcement
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Company-reported - Jun 9, 2026 · Shareholder vote
Humacyte reports results of a shareholder vote (Form 8-K, Item 5.07)
Regulatory filing - May 4, 2026 · Listing notice
Humacyte reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
Regulatory filing
Profile
- Legal name
- Humacyte, Inc.
- Listing
- Nasdaq HUMA
- SEC filer
- CIK 0001818382 ↗
- SEC industry code
- Biological Products, (No Diagnostic Substances)
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Humacyte
Anything new from Humacyte lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestUS federal awards
From USAspending.gov. Obligated is money the government has committed, not company revenue and not the contract’s potential ceiling. Outlays is what has actually been paid. Totals: $1.6 million obligated, $0.00 paid out across 1 award.
| Agency | Description | Obligated | Paid out | Period | Record |
|---|---|---|---|---|---|
| National Institutes of Health | IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR B… | $1.6 million | Not stated | Nov 14, 2013 – Nov 14, 2016 | USAspending ↗ |